Author: Charmaine Fraser

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a new contract with its valued and long-standing client, Numab Therapeutics AG (“Numab Therapeutics”).   This project reflects the continued application of Physiomics’ modelling expertise across Numab Therapeutics’ pipeline to accelerate the development of innovative therapies, building further on the...

Physiomics plc (AIM: PYC), announces an award of share options (the “Options”) over ordinary shares of 0.4 pence each in the capital of the Company (“Ordinary Shares”). The Company considers that it is important to incentivise its key employees to create shareholder value and, as such, today the Board has approved the award of the following options to Mr Jesse Thissen, Head of Biometrics, under...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a follow on contract with an existing UK based-client.   This new project builds on the contract award announced on 9 May 2025, under which Physiomics assisted its client in developing a population Pharmacokinetic (PK) model to inform the design...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a new contract with its valued and long-standing client, Numab Therapeutics AG.   This latest project will use modelling and simulation approaches to support the pre-clinical development of a multi-specific antibody in the Numab Therapeutics pipeline, under development for the...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a new contract in the biometrics department with a new client, GARDP Foundation (“GARDP”). GARDP is a not-for-profit research and development organisation that addresses global public health needs by developing new or improved antibiotic treatments, while endeavouring to...

TR-1: Standard form for notification of major holdings Please click here to read in full...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce the award of two new modelling and simulation contracts with the total value of £29,750.   Contract Award 1: Physiomics has secured a contract with a UK-based biotech firm specialising in AI-powered drug development. Building on an earlier projects announced...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biometrics company supporting the development of new therapeutics and personalised medicine solutions, announces that Peter Sargent will be stepping down from his role as Executive Director and CEO of the Company to pursue other opportunities, with effect from 29 May 2026.   The Company has commenced its search to appoint a new CEO and further announcements...